Human milk oligosaccharides inhibit rotavirus infectivity *in vitro* and in acutely infected piglets

Shelly N. Hester[1]†, Xin Chen[2]†, Min Li[2], Marcia H. Monaco[2], Sarah S. Comstock[2], Theresa B. Kuhlenschmidt[3], Mark S. Kuhlenschmidt[1,3] and Sharon M. Donovan[1,2]*

[1]*Division of Nutritional Sciences, University of Illinois, 338 Bevier Hall, 905 S. Goodwin Avenue, Urbana, IL 61801, USA*
[2]*Department of Food Science and Human Nutrition, University of Illinois, 339 Bevier Hall, 905 S. Goodwin Avenue, Urbana, IL 61801, USA*
[3]*Department of Pathobiology, University of Illinois, 2808 Veterinary Basic Sciences Medical Building, 2001 South Lincoln, Urbana, IL 61802, USA*

Abstract

Human milk (HM) is rich in oligosaccharides (HMO) that exert prebiotic and anti-infective activities. HM feeding reduces the incidence of rotavirus (RV) infection in infants. Herein, the anti-RV activity of oligosaccharides was tested in an established *in vitro* system for assessing cellular binding and viral infectivity/replication, and also tested in a newly developed, acute RV infection, *in situ* piglet model. For the *in vitro* work, crude HMO isolated from pooled HM, neutral HMO (lacto-*N*-neotetraose, LNnT; 2′-fucosyllactose) and acidic HMO (aHMO, 3′-sialyllactose, 3′-SL; 6′-sialyllactose, 6′-SL) were tested against the porcine OSU strain and human RV Wa strain. The RV Wa strain was not inhibited by any oligosaccharides. However, the RV OSU strain infectivity was dose-dependently inhibited by sialic acid (SA)-containing HMO. 3′-SL and 6′-SL concordantly inhibited ^{125}I-radiolabelled RV cellular binding and infectivity/replication. For the *in situ* study, a midline laparotomy was performed on 21-d-old formula-fed piglets and six 10 cm loops of ileum were isolated *in situ*. Briefly, 2 mg/ml of LNnT, aHMO mixture (40 % 6′-SL/10 % 3′-SL/50 % SA) or media with or without the RV OSU strain (1×10^7 focus-forming units) were injected into the loops and maintained for 6 h. The loops treated with HMO treatments + RV had lower RV replication, as assessed by non-structural protein-4 (*NSP4*) mRNA expression, than RV-treated loops alone. In conclusion, SA-containing HMO inhibited RV infectivity *in vitro*; however, both neutral HMO and SA with aHMO decreased *NSP4* replication during acute RV infection *in situ*.

Key words: Human milk oligosaccharides: Rotavirus: Piglets: Infection

Rotaviruses (RV) are double-stranded RNA viruses of the family Reoviridae, which are the most common viral agents causing viral gastroenteritis and diarrhoea in infants and young children worldwide. Each year, approximately 1·4 billion episodes of RV gastroenteritis (RVGE) occur in children under 5 years of age in developing countries, and half a million children die[1,2]. Vaccination is the main public health intervention to prevent RV infection. Systematic reviews of vaccine effectiveness and vaccination-impact studies in industrialised countries (USA, Europe and Australia) have demonstrated an effectiveness of 85–100 % associated with decreased hospitalisations for RVGE[3]. Vaccination-impact studies have demonstrated that the burden of RVGE has been reduced significantly since the introduction of RV vaccination[3]. However, efficacy trials in

developing countries in Africa and Asia showed that vaccine efficacy was lower than that observed in other countries, typically 40–70 %[4]. Although the efficacy of RV vaccines correlates closely with the national per capita income[5], it is unclear why vaccination is less efficacious in developing countries[6]. This reduced vaccine efficacy coupled with the high cost and barriers to a widespread distribution of RV vaccines[7] suggest that other means for preventing RV should continue to be investigated.

Human milk (HM) probably contains anti-RV components, as there is evidence that breast-fed infants have a lower incidence of diarrhoeal diseases compared with formula-fed infants[8,9]. Furthermore, HM contains a large number of functional components that actively protect the infant from

pathogenic infection and facilitate the development of a beneficial microbiota[10]. A unique aspect of HM is the particularly high concentration (5–12 g/l) of oligosaccharides (HMO)[11]. HMO have complex carbohydrate structures derived from twelve core structures made up of glucose, galactose and *N*-acetylglucosamine, with a lactose unit at the reducing end and fucose or sialic acid (SA) at the non-reducing end[11,12]. Epithelial cells express specific glycans that act as receptors for specific pathogens[13,14]. It has been shown that sialylated oligosaccharides inhibit the attachment of uropathogenic *Escherichia coli* strains[13] to the host cells, and fucosylated HMO are associated with the protection of breast-fed infants against diarrhoea caused by *Campylobacter*[15]. Due to the structural similarities of HMO to cell-surface glycans, HMO could serve as enterocyte receptor analogues for pathogens, and competitively inhibit the binding of pathogens to the intestinal epithelium, thereby protecting infants from diarrhoea[9–11].

Therefore, the objective of the present study was to evaluate the anti-RV activity of HMO. We tested HMO isolated from HM, pure neutral HMO and acidic HMO (aHMO) in established *in vitro* systems for assessing RV binding to the epithelial cells and RV infectivity/replication. Additionally, we developed an acute RV infection piglet model to determine which HMO fraction would be most efficacious *in vivo*. We hypothesised that sialylated HMO would reduce the binding and infectivity of sialic-acid-dependent RV both *in vitro* and *in vivo*.

Experimental methods

Oligosaccharides

The oligosaccharides used in the present study were as follows: lacto-*N*-neotetraose (LNnT; Abbott Nutrition); 2′-fucosyllactose (V-Labs); SA (V-Labs); 3′-sialyllactose (3′-SL; V-Labs); 6′-sialyllactose (6′-SL; V-Labs). In addition, a complex mixture of HMO (isolated HMO; iHMO) was isolated from preterm HM, provided by Dr Paula Meier (Rush University, Chicago, IL), as described by Li *et al.*[16]. A range of oligosaccharide concentrations was tested in the focus-forming unit (FFU) assay and the binding assay as described below. The concentrations used *in situ* were based on the *in vitro* results.

Rotavirus preparation

A sialidase-sensitive group A porcine RV OSU strain (P9[7], G5) was obtained from the American Type Culture Collection. The virus was propagated in MA-104 cells as described previously[17]. For the *in situ* assays, clarified RV OSU-infected cell-culture lysates were used. For the *in vitro* assays and for radioiodination, RV OSU was further purified by caesium chloride gradient centrifugation as described previously[17]. A sialidase-insensitive group A human RV strain (Wa) (P1A[8], G1) (American Type Culture Collection) was propagated in MA-104 cells, isolated and purified as described for the OSU strain with the following two modifications. The Wa strain was cultured in the presence of 0·5 µg trypsin/ml;

however, instead of using caesium chloride, the final gradient purification was accomplished using 15–60 % OptiPrep (Greiner Bio-One, Inc.) discontinuous step gradients. After centrifugation for 1 h in a NVT65 rotor (Beckman Coulter) at approximately 159 000 g (41 000 rpm), the single band at approximately 30 % down the gradient was collected and OptiPrep was removed by filtration through Vivaspin 500 100K MWCO (Sartorius Group). Viruses were treated with crystallised trypsin (final concentration 10 µg/ml; Sigma Chemical Company) for 30 min at 37°C before use in the *in vitro* or *in situ* assays.

In vitro assays

Focus-forming unit assay. The FFU assay was performed in MA-104 cells (BioWhittaker), a well-established model for studying RV infectivity *in vitro*[18,19]. MA-104 cells were grown to confluence in twenty-four-well plates. In a preliminary experiment, the trypsin-treated OSU strain or the RV Wa strain (10³ infectious units) was mixed with oligosaccharides at either 1 or 10 mg/ml for 30 min before the application to the confluent MA-104 cells. Before the infection, MA-104 cells were rinsed twice with PBS (pH 7·3), and then the oligosaccharide/RV mixture was applied to the cells in duplicate at 100 µl/well. In the oligosaccharide dose–response assay, cells were treated with the oligosaccharide/RV mixture at 37°C. 3′-SL and 6′-SL were tested at 2, 4, 6, 8, 10 and 16 mg/ml and iHMO at 2, 4, 6, 8, 10, 12, 16, 20 and 25 mg/ml. RV was held constant at 10³ FFU/well. After 30 min, the oligosaccharide/RV mixture was removed from the cells, replaced with serum-free minimum essential medium (MEM) and incubated for 24 h at 37°C in a 5 % CO$_2$ incubator. In the timing of the exposure assay, the confluent MA-104 cells were treated with HMO before or after exposure to RV or continuously (before, during and after the RV infection). For the HMO treatment before the infection, cells were exposed to 3′-SL and 6′-SL at a concentration of 4 mg/ml for 24 h or iHMO at 12 mg/ml for 4 h prior, HMO was then removed and the cells washed before the addition of RV in MEM. For the HMO treatment after the RV infection, cells were treated with RV for 30 min, and then RV was removed from the cells, the cells were washed and replaced with MEM containing 3′-SL, 6′-SL for 24 h or iHMO for 4 h at 37°C in a 5 % CO$_2$ incubator.

Quantification of the RV-infected cells was performed by peroxidase immunocytochemical detection of virus progeny as described previously[18,19]. Images of the stained cells (twenty-five images/well) were captured with a SPOT RT camera (Diagnostic Instruments, Inc.) attached to a Nikon Eclipse TS100 inverted microscope at a 10✗ magnification (Nikon, Inc.), equipped with a motorised microscope stage (Optiscan™; Prior Scientific). Viral infectivity, characterised as the number of brown-stained cells per well, was quantified by counting from digitised images using MetaMorph software (Molecular Devices Corporation). Data were expressed as a percentage of control.

Virus binding assay. ¹²⁵I-radiolabelled RV and the binding assay were prepared and performed as described previously[17]. Briefly, confluent monolayers of MA-104 cells

were dissociated with 0·05 % trypsin in 0·53 mm-EDTA (Sigma Chemical Company), and then the single cell suspension was washed twice with serum-free MEM and suspended to a density of 4×10^6 cells/ml. ^{125}I-radiolabelled RV OSU (approximately 150 000 dpm, 150 ng viral protein) in 15 μl was mixed in a 75×100 mm glass tube containing 250 μl 3′-SL (2, 4 and 8 mg/ml), 6′-SL (1, 2 and 4 mg/ml) or iHMO (8, 12, 16, 20 and 25 mg/ml) or medium alone for 30 min at 4°C. Following the addition of 500 μl of MA-104 cell suspension (2×10^6 cells), the tube was rotated end over end at 5 rpm. At time 0 and 30 min, aliquots of the mixture were layered over 200 μl of silicone/mineral in 400 μl polypropylene microcentrifuge tubes and centrifuged through the oil for 20 s at 15 000 g to separate the cells containing bound ^{125}I-radiolabelled RV OSU from the free ^{125}I-radiolabelled RV OSU remaining above the oil. The bottom of the plastic microcentrifuge tube containing the cell pellet was cut off, placed in a glass tube and radioactivity in the cell pellets was enumerated in a Packard Cobra gamma counter (Packard Instruments). After correction for binding at the 0 time point, data were expressed as a percentage of control.

In situ rotavirus infection model

All animal procedures were approved by the Institutional Animal Care and Use Committee of the University of Illinois. Piglets (n 9) were obtained from the University of Illinois Swine Research Center after receiving 48 h of colostrum. Piglets were individually housed in cages, maintaining six piglets separated by Plexiglas partitions (Evonik Industries) in environmentally controlled rooms (25°C) with radiant heaters attached to the tops of the cage to maintain an ambient temperature of 30°C. Piglets were fed a non-medicated, sow-milk replacer (Milk Specialties Global Animal Nutrition) twenty times daily at a rate of 360 ml/kg body weight per d until 21 d of age.

At 21 d of age, piglets were fasted 8 h before being sedated by an intramuscular injection of Telazol (tiletamine HCl and zolazepam HCl; Pfizer Animal Health) reconstituted with ketamine (2·2 mg/kg; Bioniche Pharma USA LLC) and xylazine (2·2 mg/kg; Akorn, Inc.). Piglets were maintained under isoflurane (98 % O_2/2 % isoflurane) for 6 h. Upon initiation of sedation, a midline laparotomy was performed, and six 10 cm loops of ileum were isolated in situ as described by Di Lorenzo et al.[20]. Beginning at the ileal–caecal junction, 10 cm sections were measured and loops were formed by tying the intestine with suture (Deknatel Silk Surgical Suture; Teleflex Medical OEM). Approximately 1 cm intervals were maintained between each loop. The following treatments were injected into the loops in a 2 ml volume: media, 2 mg/ml of neutral HMO (LNnT), 2 mg/ml of aHMO mixture (40 % 6′-SL/10 % 3′-SL/50 % SA) or each treatment + sialidase-sensitive porcine RV OSU strain (1×10^7 FFU). The RV OSU strain was activated by crystallised trypsin before the injection. This trypsinisation is required to permit RV penetration of cell membranes following cell attachment. Since the in vitro work showed that HMO did not decrease the infectivity of the human RV Wa strain, we chose to focus on the RV OSU strain for the in situ study. Given the limited number of loops that could be reasonably created within each piglet, we chose to pool the SA-containing HMO rather than test them individually in situ. Additionally, this is how aHMO would be present in the intestinal milieu of a HM-fed infant. For aHMO, we chose to mimic the total SA content of HM[12,21–26]. 6′-SL and 3′-SL were added at the reported ratio to each other and the remaining total SA was provided as free SA, assuming that some lipid or protein-bound SA could be released by sialidases in the intestine[27] or by microbial fermentation[28]. The order of the six treatment loops within a piglet was randomised between the piglets. After 6 h of treatment, piglets were euthanised by an intracardiac injection of sodium pentobarbital (60 mg/kg body weight, euthanasia-5 solution; Vortex Pharmaceuticals). The intestine was removed and flushed with ice-cold saline. Samples (1–2 cm) of ileal loops were snap-frozen in liquid N_2, as well as opened longitudinally, scraped free of mucosa and mucosal samples were snap-frozen in liquid N_2.

Cytokine and non-structural protein-4 mRNA expression

Total RNA was isolated from ileal mucosal samples (0·1 g) using the Qiagen, RNeasy Plus Mini Kit (Qiagen) following the manufacturer's protocol. RNA was quantified and quality was assessed using a Nanodrop 1000 (Thermo Scientific) and a 2100 Bioanalyzer (Agilent Technologies, Inc.), respectively. All samples had an RNA integrity number greater than 6. RT was performed with 3 μg total RNA in a reaction volume of 20 μl (High Capacity cDNA Reverse Transcription Kit; Applied Biosystems). RT products were analysed by quantitative real-time PCR using TaqMan® custom porcine-specific primers and probes (non-structural protein-4; NSP4) or gene expression assay kits for NF-κB, IL-8, TNF-α, chemokine (C–C motif) ligand 2 and IL-1β (Applied Biosystems) (Table 1). Reference complementary DNA ribosomal protein L19 was used as an endogenous control (Applied Biosystems). All reactions were analysed using the 7900HT Fast Real-Time PCR Detection System instrument and SDS 2.3 software (Applied Biosystems). Universal reaction conditions were used as follows: 2 min at 50°C and 10 min at 95°C and then forty cycles of 15 s at 95°C and 1 min at 60°C. Each reaction was run in triplicate. Cytokine expression was standardised to ribosomal protein L19 mRNA and expressed as fold difference relative to the medium control loop. NSP4 expression was standardised to ribosomal protein L19 mRNA and expressed as normalised quantity, since the control loop contained no NSP4 mRNA expression.

Statistical analyses

All statistical analyses were performed using SAS (version 6.09; SAS Institute). Data were analysed by one-way ANOVA using the general linear model procedure in SAS. For in vitro data, differences between treatment means within each oligosaccharide were analysed by Duncan's test. For in situ PCR data, outliers were identified using Cook's D test and normality was checked using the Shapiro–Wilk test. PCR data were analysed using a PROC MIXED, randomised block analysis, to determine the effects of the HMO and RV loop treatments,

Table 1. TaqMan gene expression assay kits and custom primers for quantitative real-time PCR

Genes	TaqMan gene expression assay* or primer sequence
TaqMan gene expression assay	
TNF-α	Ss03391318_g1
IL-1β	Ss03393804_m1
IL-8	Ss03392435_m1
NF-κB	Ss03388577_m1
CCL2	Ss03394377_m1
RPL19†	Ss03375624_g1
Primer sequence	
NSP4	Forward: CAT TGG ACC CGA TGG TTG AC
	Reverse: GCT GAG CCA CAC GCG ATAT
	Probe: 6fam AGA AGC CAC AGT CAA TMGB

CCL2, chemokine (C–C motif) ligand 2; RPL19, ribosomal protein L19; NSP4, non-structural protein-4.
* Applied Biosystems.
† Reference complementary DNA.

and their interactions. The interactions were removed from the model if not significant. In the event of a significant main effect, a *post hoc* least significant difference test was used to compare differences among the treatments. All data are reported as means and standard deviations. Statistical significance was set at $P<0.05$.

Results

In vitro *studies*

The composition of the isolated crude HMO as determined by HPLC-chip/time-of-flight MS has been reported previously[16]. Approximately 25·1% of HMO were neither fucosylated or sialylated; LNnT/lacto-N-tetrose (LNT) accounted for 16·1% of total iHMO. Fucosylated oligosaccharides accounted for 30·9% of total iHMO, of which 2′-fucosyllactose consisted of 5·8% of total iHMO. Sialylated oligosaccharides comprised 31·6% of total iHMO, of which 3′-SL and 6′-SL comprised 1·1

and 2·1% of total iHMO, respectively. HMO containing both fucose and SA accounted for 12·4% of total iHMO[16].

Focus-forming unit assay. To initially screen the effective concentration range of oligosaccharides against RV infectivity in MA-104 cells, 1 and 10 mg/ml concentrations were tested in the FFU assay. The infectivity of the RV OSU strain was not inhibited by any oligosaccharides at 1 mg/ml. At 10 mg/ml, a significant inhibition of OSU infectivity was observed for 3′-SL (85% inhibition), 6′-SL (90% inhibition) and iHMO (33% inhibition) ($P<0.05$). The LNnT and 2′-fucosyllactose treatments at either 1 or 10 mg/ml did not reduce RV OSU infectivity (data not shown). Human RV Wa strain infectivity was not inhibited by any oligosaccharides at either dose; therefore, no further analyses were conducted using the RV Wa strain.

To define the optimal HMO concentration to inhibit the RV OSU strain *in vitro*, 3′-SL and 6′-SL were screened from 2 to 16 mg/ml and iHMO from 2 to 25 mg/ml (Fig. 1). Compared with the control, a dose-dependent reduction of RV infectivity was observed between 2 and 6 mg/ml for 3′-SL (20–74%

Fig. 1. Dose-dependent inhibition of porcine rotavirus OSU strain infectivity in MA-104 cells by sialylated human milk oligosaccharides (HMO) and isolated HMO (–△–). Values are means as a percentage of control, with standard deviations represented by vertical bars (*n* 6). a,b,c,d,e Mean values with unlike letters within each oligosaccharide were significantly different ($P<0.05$). –○–, 3′-Sialyllactose; –●–, 6′-sialyllactose.

inhibition, $P<0.05$) and 6′-SL (61–83 % inhibition, $P<0.05$). In addition, 6′-SL was significantly more effective than 3′-SL at 2 and 4 mg/ml. At 6 mg/ml, the percentage of inhibition by 6′-SL and 3′-SL was similar, and no further reduction in RV infectivity was observed at concentrations greater than 4 mg/ml for 6′-SL and 6 mg/ml for 3′-SL. iHMO did not significantly reduce RV infectivity at concentrations between 2 and 6 mg/ml, whereas a significant reduction (26 % inhibition) was reached at the concentration of 8 mg/ml. No further inhibition was detected at concentrations greater than 20 mg/ml. Approximately 50 % inhibition of RV infectivity was achieved at 4 mg/ml for 3′-SL, 2 mg/ml for 6′-SL and 12 mg/ml for iHMO, respectively ($P<0.05$).

Data in Fig. 1 reflect exposure to HMO only during the RV infection phase. Therefore, to investigate the effect of the timing of exposure to HMO on RV infectivity, MA-104 cells were incubated with 3′-SL (4 mg/ml), 6′-SL (4 mg/ml) or iHMO (12 mg/ml) before and/or after the RV infection, or were present in the media before, during and after the RV infection (Fig. 2). In all the treatment scenarios, 6′-SL significantly reduced RV infectivity by 16–96 % when present at any phase ($P<0.05$). Neither 3′-SL nor iHMO reduced RV infectivity when the cells were treated before the infection; however, exposure to these treatments after the RV infection reduced RV infectivity compared with the control ($P<0.05$). Continuous exposure to any HMO treatment was most effective in reducing RV infectivity.

Virus binding assay. The ability of the oligosaccharides to block the binding of RV to MA-104 cells was tested using the ^{125}I-labelled RV OSU strain (Fig. 3). Both 6′-SL and 3′-SL significantly reduced RV cellular binding at 1 and 2 mg/ml, respectively ($P<0.05$), while iHMO inhibited virus binding at concentrations between 8 and 25 mg/ml ($P<0.05$). A 50 % inhibition of RV binding was observed at the concentration of 4 mg/ml for 3′-SL, 2 mg/ml for 6′-SL and 16 mg/ml for iHMO, respectively.

## In situ rotavirus infection model

Body weight and formula intake. Piglets were healthy and grew normally throughout the study. Average body weights of piglets at 2 and 21 d of age were 1·9 (SD 0·4) and 5·5 (SD 0·5) kg, respectively. Formula intake at 21 d of age was 1·89 (SD 0·32) litres/d.

Ileal mucosa mRNA expression. Ileal mucosa from the loops treated with either aHMO (40 % 6′-SL/10 % 3′-SL/50 % SA) or LNnT + RV had lower RV replication, as assessed by *NSP4* mRNA expression, than that from the RV-treated loop ($P=0.007$) (Fig. 4). Ileal loops not exposed to RV had no *NSP4* expression. There were no differences in the ileal mucosa mRNA expression of *NF-κB*, *TNF-α*, chemokine (C–C motif) ligand 2, *IL-8* or *IL-1β* among the treatments (Table 2).

Discussion

Breast-feeding reduces the incidence of RVGE[8], a major cause of morbidity and mortality worldwide. HM contains high concentrations of HMO, which are known to block the attachment of pathogens to the intestinal cells[13–15]. However, the anti-RV activity of specific HMO has been insufficiently studied. RV strains are generally classified as sialidase-sensitive or -insensitive according to their dependence on the presence of SA on the cell surface for efficient binding and infectivity[28,29,30]. The present study tested the

Fig. 2. Impact of the timing of exposure to human milk oligosaccharides (HMO) on the infectivity of the porcine rotavirus (RV) OSU strain in MA-104 cells. Values are means as a percentage of control, with standard deviations represented by vertical bars (n 6). [a,b,c,d,e] Mean values with unlike letters within each oligosaccharide were significantly different ($P<0.05$). ■, 3′-Sialyllactose; ▨, 6′-sialyllactose; □, isolated HMO.

Fig. 3. Dose-dependent inhibition of porcine rotavirus OSU strain binding to MA-104 cells by sialylated human milk oligosaccharides (HMO) and isolated HMO (–△–). Values are means as a percentage of control, with standard deviations represented by vertical bars (*n* 5). [a,b,c,d] Mean values with unlike letters within each oligosaccharide were significantly different (*P*<0·05). –○–, 3′-Sialyllactose; –●–, 6′-sialyllactose.

hypothesis that HMO, particularly sialylated HMO, would reduce RV infectivity by inhibiting the binding of a SA-dependent RV to the epithelial cells. Consistent with this hypothesis, the present results demonstrated that infectivity of porcine RV OSU strain was inhibited by sialylated HMO (3′-SL and 6′-SL) and by the iHMO mixture *in vitro*, but not by neutral oligosaccharides (LNnT and 2′-fucosyllactose). We did not include free SA in the FFU or binding assays as previous work in our laboratory demonstrated no inhibition of porcine RV OSU strain[31], although Koketsu *et al.*[32] have shown that

1 mg/ml of free SA inhibited the binding of SA-dependent simian SA-11 RV strain to MA-104 cells by 40 %.

These results are in agreement with previous studies showing that the infectivity of SA-dependent strains of RV was reduced in the presence of SA-containing compounds[31,32]. Bergner *et al.*[33] reported that a sialyllactose-containing neoglycolipid reduced RV OSU strain binding to MA-104 cells and in newborn piglets. Similarly, sialyloligosaccharides isolated from egg yolk hindered the infectivity of a SA-dependent strain of RV isolated from simians (SA-11),

Fig. 4. Acidic human milk oligosaccharide (aHMO) mixture (40 % 6′-sialyllactose/10 % 3′-sialyllactose/50 % sialic acid) and lacto-*N*-neotetraose (LNnT) reduce mucosal non-structural protein-4 (NSP4) mRNA expression in the ileal mucosa of acutely rotavirus (RV)-infected piglets. Values are means, with standard deviations represented by vertical bars. The expression levels of NSP4 were standardised to ribosomal protein L19 mRNA and expressed as normalised target. [a,b] Mean values with unlike letters were significantly different (*P*<0·05).

Table 2. Cytokine and transcription factor mRNA abundance in piglet ileal mucosa is unaffected by the rotavirus (RV) or human milk oligosaccharides (HMO) treatments*

(Mean values and standard deviations)

	Loop treatments (2 mg HMO/ml)											
	Media		LNnT		aHMO†		RV OSU strain (10^7)					
							Media		LNnT		aHMO†	
	Mean	SD	Mean	SD	Mean	SD	Mean	SD	Mean	SD	Mean	SD
CCL2	1·0	0	1·6	0·9	1·3	0·4	1·2	0·3	1·1	0·2	1·6	0·4
IL-1β	1·0	0	1·3	0·3	1·1	0·2	1·2	0·2	1·2	0·3	1·1	0·3
IL-8	1·0	0	1·5	0·3	1·0	0·3	1·3	0·6	1·4	0·4	1·3	0·4
NF-κB	1·0	0	1·0	0·2	1·2	0·2	1·6	0·3	1·1	0·2	1·4	0·3
TNF-α	1·0	0	1·3	0·4	1·1	0·3	2·0	0·4	1·7	0·6	1·7	0·3

LNnT, lacto-*N*-neotetraose; aHMO, acidic HMO; *CCL2*, chemokine (C−C motif) ligand 2.

* Cytokine expression was standardised to ribosomal protein L19 mRNA and expressed as fold difference relative to the medium control loop.

† aHMO mixture comprised 40 % 6′-sialyllactose/10 % 3′-sialyllactose/50 % sialic acid.

both *in vitro* and *in vivo* [34]. Consistent with this structural specificity for the inhibition of binding, the infectivity of the human RV Wa strain was not prevented by 3′-SL or 6′-SL, which is known to be a SA-insensitive RV strain[35]. RV Wa strain infectivity was also not inhibited by neutral HMO or the complex mixture of HMO isolated from HM. Since many RV strains that infect humans are non-SA-dependent[35], it is possible that other HM components are responsible for the lower incidence of RVGE in breast-fed infants[8,9]. For example, HM contains antibodies against RV, and proteins in the milk-fat-globule membrane, including lactadherin, have been shown to inhibit RV replication[36−38]. Thus, HM contains components that may provide broad-spectrum protection against both SA-dependent and -independent strains.

The dose−response experiment showed that both 6′-SL and 3′-SL reduced RV OSU infectivity by 50 % at concentrations of 2 and 4 mg/ml, respectively. The results are consistent with Rolsma *et al.*[19], who found that the amount of 3′-SL to inhibit RV OSU binding by 50 % in MA-104 cells was greater than that of 6′-SL. Thus, 6′-SL is more effective in obstructing RV OSU infectivity than its isomer 3′-SL, possibly due to a greater affinity of sialylated HMO for SA-containing cellular receptors.

The concentration of the iHMO mixture needed to inhibit RV infectivity was in the range of 8−20 mg/ml, which is within the range of the concentrations of HMO (5−12 g/l)[12], implying that physiological concentrations of HMO could have the potential to inhibit RV infection. Analysis of iHMO by MS demonstrated that sialylated HMO comprised 31·6 % of total HMO[16], which supports the lower efficacy of iHMO, if SA-containing HMO were the most effective in impeding RV OSU infectivity.

The mechanisms by which 3′-SL, 6′-SL and HMO inhibited RV OSU strain infectivity were investigated in two ways. First, the effect of the timing of exposure to HMO on RV infectivity was determined. All three oligosaccharides inhibited RV infectivity when MA-104 cells were treated during and after the infection, indicating that HMO could modulate RV infectivity by blocking entry into the cell and/or by affecting viral replication. A slight inhibition of RV infectivity was also observed when MA-104 cells were pretreated with 6′-SL

before the infection, which was not the case for 3′-SL- and HMO-treated cells. These data show that continual exposure to HMO was most effective in inhibiting the infection, which is what a breast-fed baby would experience. However, iHMO were also effective when the cells were exposed post-RV exposure, suggesting an opportunity to use HMO therapeutically in oral rehydration solutions or specialised formulae for children already infected with RV to reduce the severity and duration of the disease.

Second, whether 3′-SL, 6′-SL and HMO directly blocked RV binding to the host cells was investigated using the ^{125}I-labelled RV OSU strain. Comparing the results of the FFU infectivity assay *v.* the binding assay, there was a concordance between the inhibition of RV binding and infectivity/replication for 3′-SL and 6′-SL, supporting the blocking of RV binding as the primary mechanism of action by SA-containing HMO. These findings are also consistent with Yolken *et al.*[39], who showed that SA-containing glycoproteins inhibited RV binding and replication *in vitro* and *in vivo*. In contrast, at a physiological concentration (12 mg/ml), the iHMO mixture was less effective in inhibiting RV binding (30 % inhibition) than replication (53 % inhibition), implying that HMO also acts at a post-binding step. Recent studies have shown that HMO can reduce intestinal cell proliferation and induce apoptosis[40,41]; thus, HMO may reduce the ability of RV to replicate within the cells by altering intestinal cell turnover.

To determine whether HMO inhibit RV infectivity *in vivo*, we developed a novel piglet model of acute RV infection in which multiple 10 cm loops were created in the ileum *in situ*. HMO with or without the RV OSU strain was introduced into the loops and samples were collected at 6 h post-infection. Expression of RV *NSP4* gene in ileal mucosa was used as an indicator of RV viral replication *in vivo*. The triple-layered RV contains a genome of eleven segments of double-stranded RNA that codes for six structural and five non-structural proteins. *NSP4* is one of the first viral genes transcribed in the host cell. In addition, it is important in the pathophysiology of RV in that it can lead to a mobilisation of intracellular

Ca[42], and purified NSP4 can induce diarrhoea in young mice when injected intraperitoneally or intraileally[43].

Mucosa from RV-infected ileal loops displayed a high level of RV *NSP4* mRNA expression. However, no *NSP4* replication was detected in the loops not treated with RV. Thus, viral infection was confined to the challenged loops and absent from the adjacent loops. The advantage of this approach is that it is possible to compare host responses to RV-infected and non-infected ileum within the same animal. Additionally, due to the low volume required within the loops, this model provides an ideal screening tool for the efficacy of multiple components that may only be available in limited quantities, such as HMO.

We observed that RV-infected ileal loops co-incubated with either aHMO (40 % 6′-SL/10 % 3′-SL/50 % SA) or LNnT had significantly lower *NSP4* mRNA expression than the loop exposed to RV alone. The inhibition of RV replication by aHMO *in situ* confirmed the present *in vitro* observation that SA-containing HMO are effective inhibitors of RV infectivity. Our aHMO mix included free SA, 3′-SL and 6′-SL. We demonstrated herein that 3′-SL and 6′-SL reduce RV OSU strain binding and replication *in vitro*. The mixture used in the *in situ* model contained 50 % SA and may have different effects on RV infectivity as HMO bound SA in the same concentration. Although our previous work did not show the inhibition of RV OSU strain by free SA[31], Koketsu *et al.*[32] showed that 1 mg/ml of free SA, which is comparable with that included in the aHMO mix, inhibited the binding of another SA-dependent RV strain (SA-11) by 40 %. Therefore, we cannot rule out that free SA also contributed to reduced RV replication *in situ*.

On the basis of the present *in vitro* observations, we anticipated that LNnT would not inhibit RV infectivity. However, *NSP4* expression was also reduced when RV was co-incubated with LNnT. It is possible that LNnT within the milieu of the ileum is able to inhibit RV binding or entry into the cell, an effect which could not be observed in the *in vitro* FFU assay. Although this result was unexpected, there are several potential explanations for this observation, through altering the host immune response, inhibiting the binding of RV or altering the intraluminal milieu. First, HMO are immunomodulatory due to their ability to interact directly with intestinal epithelial cells[44]. Terrazas *et al.*[45] demonstrated that injection of LNnT into mice increased a population of cells (Gr1+CD11b+F4/80+) that secreted anti-inflammatory cytokines (IL-10, transforming growth factor-β) as early as 2 h post-injection. Furthermore, co-culturing these cells with naive CD4+ T cells suppressed T-cell proliferation and programmed naive CD4+ T cells to secrete lower levels of interferon-γ coincident with increased IL-13 production. Thus, injection of LNnT generated anti-inflammatory mediators that suppressed T helper 1 (Th1)-type and inflammatory responses[45]. To date, there is no direct evidence for the inhibition of RV binding or infectivity by LNnT. However, both sialylated and non-sialylated LNnT structures were found to be present in lipo-oligosaccharides of *Neisseria meningitidis* and may play a role in cellular recognition by this pathogen[46]. Lastly, LNnT may be fermented by the microbiota in the

ileum, leading to the production of SCFA in the intraluminal environment. We recently demonstrated that LNnT was fermented by piglet gut microbiota[16]. LNnT produced larger amounts of gas, total SCFA, acetate and butyrate than did other substrates (polydextrose/galacto-oligosaccharides, short-chain fructo-oligosaccharides or iHMO)[16]. Previous studies have shown that SCFA inhibit the replication of bovine enterovirus, but were almost ineffective against other viruses such as poliovirus type 1, coxsackievirus B5, encephalomyocarditis virus and human rhinovirus 1B[47]. Ismail-Cassim *et al.*[47] showed that lauric acid could bind to bovine enterovirus. Virions with lauric acid bound to it were able to attach to cells, but failed to undergo cell-mediated uncoating. The inhibitory effect is reversible with chloroform and may result from a hydrophobic interaction between the fatty acid and a specific site on the virus particle[47]. One or more of these actions may be at work in the LNnT-treated loops, thereby preventing RV infection/replication and the subsequent increase in *NSP4* mRNA expression. Although these mechanisms may be at play, further research is needed to determine the direct mechanism of inhibition by LNnT.

RV infection leads to an up-regulation of cytokine gene expression. Following a RV infection in MA-104 cells, an increase in the protein abundance of the *NF-κB* transcription factor was detected at 2 h[48] and the maximum rate of viral RNA synthesis was achieved at 3 h[49]. Work in our laboratory in the RV-infected piglet showed an increase of NF-κB nuclear protein abundance in the jejunal mucosa at 4 h post-infection[50]. Accordingly, we anticipated that *NF-κB* and cytokine mRNA expression would be up-regulated at 6 h following an RV infection in the ileum. However, no statistically significant differences in gene expression were observed between the RV-infected and non-infected loops for any gene tested. This may be due to the fact that we measured *NF-κB* mRNA expression, rather than nuclear protein abundance. Since NF-κB present in the inactive form in the cytosol is bound to inhibitor of κB (IκB), it would not require time for transcription or translation and could be more rapidly detected than *NF-κB* mRNA. Therefore, 6 h may have been insufficient time for the acute RV infection *in situ* to cause transcription factor and cytokine expression differences in the ileum.

In summary, SA-containing HMO and SA-containing HMO with SA effectively inhibit the infection caused by SA-dependent RV OSU strain both *in vitro* and *in vivo*. *In vitro* findings support several possible mechanisms: by inhibiting RV binding to the host cells and/or modulating the process of RV entry into the cell or viral replication. The present paper reports for the first time that both neutral (LNnT) and aHMO with free SA significantly decreased RV replication in the *in situ* model. Although the mechanisms of RV infectivity inhibition remain to be further investigated, the present study demonstrates the potential of HMO to reduce RV infection. Thus, these results suggest that HMO could be useful for preventing RV infection in young animals and human infants. The novel *in situ* loop model provides a sensitive system in which to rapidly screen HMO and other ingredients for anti-RV activity. This model can thus be used to guide the design of *in vivo* feeding studies in piglets or human infants.

References

1. Parashar UD, Burton A, Lanata C, *et al.* (2009) Global mortality associated with rotavirus disease among children in 2004. *J Infect Dis* **200**, Suppl. 1, S9–S15.
2. Tate JE, Burton AH, Boschi-Pinto C, *et al.* (2012) 2008 Estimate of worldwide rotavirus-associated mortality in children younger than 5 years before the introduction of universal rotavirus vaccination programmes: a systematic review and meta-analysis. *Lancet Infect Dis* **12**, 136–141.
3. Giaquinto C, Dominiak-Felden G, Van Damme P, *et al.* (2011) Summary of effectiveness and impact of rotavirus vaccination with the oral pentavalent rotavirus vaccine: a systematic review of the experience in industrialized countries. *Hum Vaccin* **7**, 734–748.
4. Cherian T, Wang S & Mantel C (2012) Rotavirus vaccines in developing countries: the potential impact, implementation challenges, and remaining questions. *Vaccine* **30**, Suppl. 1, A3–A6.
5. Holmgren J & Svennerholm AM (2012) Vaccines against mucosal infections. *Curr Opin Immunol* **24**, 343–353.
6. Perez-Schael I, Salinas B, Tomat M, *et al.* (2007) Efficacy of the human rotavirus vaccine RIX4414 in malnourished children. *J Infect Dis* **196**, 537–540.
7. Clemens J (2011) Evaluation of vaccines against enteric infections: a clinical and public health research agenda for developing countries. *Philos Trans R Soc Lond B Biol Sci* **366**, 2799–2805.
8. Plenge-Bönig A, Soto-Ramírez N & Karmaus W (2010) Breastfeeding protects against acute gastroenteritis due to rotavirus in infants. *Eur J Pediatr* **169**, 1471–1476.
9. Newburg DS, Ruiz-Palacios GM & Morrow AL (2005) Human milk glycans protect infants against enteric pathogens. *Annu Rev Nutr* **25**, 37–58.
10. Donovan SM (2006) Role of human milk components in gastrointestinal development: current knowledge and future needs. *J Pediatr* **149**, Suppl. 3, 49.
11. Morrow AL & Rangel JM (2004) Human milk protection against infectious diarrhea: implications for prevention and clinical care. *Semin Pediatr Infect Dis* **15**, 221–228.
12. Kunz C, Rudloff S, Baier W, *et al.* (2000) Oligosaccharides in human milk: structural, functional, and metabolic aspects. *Annu Rev Nutr* **20**, 699–722.
13. Martin-Sosa S, Martin MJ & Hueso P (2002) The sialylated fraction of milk oligosaccharides is partially responsible for binding to enterotoxigenic and uropathogenic *Escherichia coli* human strains. *J Nutr* **132**, 3067–3073.
14. Morrow AL, Ruiz-Palacios GM, Jiang X, *et al.* (2005) Human-milk glycans that inhibit pathogen binding protect breast-feeding infants against infectious diarrhea. *J Nutr* **135**, 1304–1307.
15. Ruiz-Palacios GM, Calva JJ, Pickering LK, *et al.* (1990) Protection of breast-fed infants against *Campylobacter* diarrhea by antibodies in human milk. *J Pediatr* **116**, 707–713.
16. Li M, Bauer LL, Chen X, *et al.* (2012) Microbial composition and *in vitro* fermentation patterns of human milk oligosaccharides and prebiotics differ between formula-fed and sow-reared piglets. *J Nutr* **142**, 681–689.
17. Rolsma MD, Gelberg HB & Kuhlenschmidt MS (1994) Assay for evaluation of rotavirus–cell interactions: identification of an enterocyte ganglioside fraction that mediates group A porcine rotavirus recognition. *J Virol* **68**, 258–268.
18. Andres A, Donovan SM, Kuhlenschmidt TB, *et al.* (2007) Isoflavones at concentrations present in soy infant formula inhibit rotavirus infection *in vitro*. *J Nutr* **137**, 2068–2073.
19. Rolsma MD, Kuhlenschmidt TB, Gelberg HB, *et al.* (1998) Structure and function of a ganglioside receptor for porcine rotavirus. *J Virol* **72**, 9079–9091.
20. Di Lorenzo M, Bass J & Krantis A (1995) An intraluminal model of necrotizing enterocolitis in the developing neonatal piglet. *J Pediatr Surg* **30**, 1138–1142.
21. Wang B, Brand-Miller J, McVeagh P, *et al.* (2001) Concentration and distribution of sialic acid in human milk and infant formulas. *Am J Clin Nutr* **74**, 510–515.
22. Miller JB, Bull S, Miller J, *et al.* (1994) The oligosaccharide composition of human milk: temporal and individual variations in monosaccharide components. *J Pediatr Gastroenterol Nutr* **9**, 371–376.
23. Nakanto T, Sugawara M & Kawakami H (2001) Sialic acid in human milk: composition and functions. *Acta Paediatr Taiwan* **42**, 11–17.
24. Thurl S, Munzert M, Henker J, *et al.* (2010) Variation of human milk oligosaccharides in relation to milk groups and lactational periods. *Br J Nutr* **104**, 1261–1271.
25. Bao Y, Zhu L & Newburg DS (2007) Simultaneous quantification of sialyloligosaccharides from human milk by capillary electrophoresis. *Anal Biochem* **370**, 206–214.
26. Martín-Sosa S, Martín MJ, García-Pardo LA, *et al.* (2003) Sialyloligosaccharides in human and bovine milk and in infant formulas: variations with the progression of lactation. *J Dairy Sci* **86**, 52–59.
27. Dickson JJ & Messer M (1978) Intestinal neuraminidase activity of suckling rats and other mammals. *Biochem J* **170**, 407–413.
28. Brand-Miller JC, McVeagh P, McNeil Y, *et al.* (1998) Digestion of human milk oligosaccharides by healthy infants evaluated by the lactulose hydrogen breath test. *J Pediatr* **133**, 95–98.
29. Isa P, Arias CF & Lopez S (2006) Role of sialic acids in rotavirus infection. *Glycoconj J* **23**, 27–37.
30. Haselhorst T, Fleming FE, Dyason JC, *et al.* (2009) Sialic acid dependence in rotavirus host cell invasion. *Nat Chem Biol* **5**, 91–93.
31. Ochonicky KL (2005) Inhibitory effects of human and porcine milk oligosaccharides on sialic acid-dependent and -independent strains of rotavirus. MS Thesis, University of Illinois.

32. Koketsu M, Nitoda T, Sugino H, *et al.* (2011) Synthesis of a novel sialic acid derivative (sialylphospholipid) as an antirotaviral agent. *J Med Chem* **1997**, 3332–3335.

33. Bergner DW, Kuhlenschmidt TB, Hanafin WP, *et al.* (2011) Inhibition of rotavirus infectivity by a neoglycolipid receptor mimetic. *Nutrients* **3**, 228–244.

34. Koketsu M, Nitoda T, Juneja LR, *et al.* (1995) Sialyloligosaccharides from egg yolk as an inhibitor of rotaviral infection. *J Agric Food Chem* **43**, 858.

35. Ciarlet M & Estes MK (1999) Human and most animal rotavirus strains do not require the presence of sialic acid on the cell surface for efficient infectivity. *J Gen Virol* **80**, 943–948.

36. Bojsen AJ, Buesa R, Montava AS, *et al.* (2007) Inhibitory activities of bovine macromolecular whey proteins on rotavirus infections *in vitro* and *in vivo*. *J Dairy Sci* **90**, 66–74.

37. Newburg DS, Peterson JA & Ruiz-Palacios GM (1998) Role of human-milk lactadherin in protection against symptomatic rotavirus infection. *Lancet* **351**, 1160–1164.

38. Kvistgaard AS, Pallesen LT & Arias CF (2004) Inhibitory effects of human and bovine milk constituents on rotavirus infections. *J Dairy Sci* **87**, 4088–4096.

39. Yolken RH, Willoughby R, Wee SB, *et al.* (1987) Sialic acid glycoproteins inhibit *in vitro* and *in vivo* replication of rotaviruses. *J Clin Invest* **79**, 148–154.

40. Kuntz S, Rudloff S & Kunz C (2008) Oligosaccharides from human milk influence growth-related characteristics of intestinally transformed and non-transformed intestinal cells. *Br J Nutr* **99**, 462–471.

41. Kuntz S, Kunz C & Rudloff S (2009) Oligosaccharides from human milk induce growth arrest via G2/M by influencing growth-related cell cycle genes in intestinal epithelial cells. *Br J Nutr* **101**, 1306–1315.

42. Hyser JM, Collinson-Pautz MR, Utama B, *et al.* (2010) Rotavirus disrupts calcium homeostasis by NSP4 viroporin activity. *MBio* **1**, e00265–e00275.

43. Ball JM, Tian P, Zeng CQ, *et al.* (1996) Age-dependent diarrhea induced by a rotaviral nonstructural glycoprotein. *Science* **272**, 101–104.

44. Kunz C & Rudloff S (2008) Potential anti-inflammatory and anti-infectious effects of human milk oligosaccharides. *Adv Exp Med Biol* **606**, 455–465.

45. Terrazas LI, Walsh KL, Piskorska D, *et al.* (2001) The schistosome oligosaccharide lacto-*N*-neotetraose expands Gr1(+) cells that secrete anti-inflammatory cytokines and inhibit proliferation of naive CD4(+) cells: a potential mechanism for immune polarization in helminth infections. *J Immunol* **167**, 5294–5303.

46. Tsai CM (2001) Molecular mimicry of host structures by lipooligosaccharides of *Neisseria meningitidis*: characterization of sialylated and nonsialylated lacto-*N*-neotetraose (Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc) structures in lipooligosaccharides using monoclonal antibodies and specific lectins. *Adv Exp Med Biol* **491**, 525–542.

47. Ismail-Cassim N, Chezzi C & Newman JF (1990) Inhibition of the uncoating of bovine enterovirus by short chain fatty acids. *J Gen Virol* **71**, 2283–2289.

48. Rollo EE, Kumar KP, Reich NC, *et al.* (1999) The epithelial cell response to rotavirus infection. *J Immunol* **163**, 4442–4452.

49. Stacy-Phipps S & Patton JT (1987) Synthesis of plus- and minus-strand RNA in rotavirus-infected cells. *J Virol* **61**, 3479–3484.

50. Andres A, Taylor SA, Helregel BA, *et al.* (2007) Gastrointestinal adaptive and innate immunological responses to rotavirus infection in the neonatal piglet. *Gastroenterology* **131**, A715.